Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 7/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147406 | 0.90 | RET (0.43) | RETOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20147915 | 0.83 | RET (0.39) | RETCNR2EGLN1CNR1ALDH1A1 | |
| SCHEMBL20158576 | 0.83 | RET (0.41) | RETCNR2EGLN1CNR1 | |
| SCHEMBL20147914 | 0.78 | CYP46A1 (0.48) | RETOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20069493 | 0.74 | RET (0.43) | RETOPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20069298 | 0.74 | DRD2 (0.36) | RETCNR2EGLN1ALDH1A1 | |
| SCHEMBL20069415 | 0.73 | RET (0.49) | RETCNR2 | |
| SCHEMBL20137738 | 0.73 | POLB (0.53) | RETOPRD1OPRK1ALDH1A1 | |
| SCHEMBL25502481 | 0.69 | HTR1A (0.37) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL20205813 | 0.69 | RET (0.35) | RETOPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885OPRM1 3497/4885OPRD1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.